|
|
Article: Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia.
- Article from:
- PR Newswire
- Article date:
- August 28, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at 11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST
The Evotec speakers at the worldsleep07 congress and in the webcast and conference call will be:
- Dr John Kemp, Chief Research and Development Officer
- Dr Tim Tasker, Executive Vice President Clinical Development
Evotec will host a poster presentation on the study results at the worldsleep07 ...